HRT for men: a clinician-grounded guide to testosterone therapy. - Reddit

What is HRT for men, and how does it differ from anabolic steroid use?

The term “HRT for men” is often used interchangeably with testosterone replacement therapy. Technically, male HRT is a broader category that can include testosterone, DHEA, thyroid hormone (in men with thyroid dysfunction), and in some protocols, estrogen management — but testosterone is the central component and what most people mean when they ask about male HRT.

TRT is a clinician-supervised medical treatment, not a performance enhancement protocol. Its purpose is to restore testosterone to a physiologically normal range in men who have a documented deficiency. The clinical term for this condition is hypogonadism. The Endocrine Society guidelines define treatment candidacy by the combination of confirmatory low lab values and clinical symptoms — not either alone.

This distinction matters because TRT involves an FDA-approved medication (testosterone is a Schedule III controlled substance in the US) with well-characterized effects at replacement doses, a rigorous monitoring protocol, and a distinct risk profile from anabolic steroid misuse.

How does testosterone decline with age in men?

Testosterone levels in men peak in the late teens to mid-twenties and decline at roughly 1–2% per year starting in the 30s. By the time a man reaches his 40s or 50s, cumulative decline can be significant enough to produce symptoms — even if absolute levels remain within the broad laboratory reference range.

This is one of the more nuanced aspects of TRT evaluation: laboratory reference ranges are population-based averages that span a wide range (roughly 300–1000 ng/dL in most labs). A man with a testosterone level of 310 ng/dL is technically “normal” by most lab cutoffs — but if his levels were 750 ng/dL a decade earlier, the functional decline may be clinically meaningful. A competent TRT evaluation considers the whole picture: labs, symptom burden, health history, and baseline.

Who is a candidate for TRT, and what does the evaluation require?

Endocrine Society guidelines recommend TRT evaluation when a man has:

• Documented low testosterone: Total testosterone consistently below 300 ng/dL on two separate morning draws (morning because testosterone is highest in the AM). Free testosterone levels may also be relevant when SHBG (sex hormone binding globulin) is elevated, as it reduces the bioavailable fraction.
• Clinical symptoms of hypogonadism: Including reduced energy, low libido, difficulty maintaining muscle mass, increased body fat (particularly visceral fat), mood changes, cognitive fog, or reduced bone density. The presence and severity of symptoms helps determine treatment urgency.
• No contraindications: Absolute contraindications include untreated prostate or breast cancer, polycythemia vera, severe uncontrolled heart failure, and active desire for fertility without concurrent HCG. Relative contraindications and risk factors require clinical judgment.

Men who have symptoms but normal testosterone, or low testosterone without symptoms, are not standard TRT candidates under evidence-based guidelines. Your clinician will also investigate and rule out secondary causes of low T (pituitary dysfunction, thyroid issues, sleep apnea, obesity) before starting testosterone.

What testosterone formulations are available, and how do they differ?

The delivery routes below span FDA-approved brand and generic testosterone products as well as compounded alternatives (503A pharmacy preparations, which are not FDA-approved as finished products). Your clinician will match the delivery method to your clinical needs, lifestyle, and preferences:

Injectable testosterone (cypionate or enanthate)

The most widely used TRT method in the US. Testosterone cypionate and enanthate are long-acting esters administered subcutaneously or intramuscularly, typically weekly or twice weekly. Subcutaneous injection with small-gauge (27–29G) needles has become increasingly preferred for its convenience and tolerability. Injectables provide predictable pharmacokinetics and are generally the most cost-effective option for self-pay patients.

Topical gels and creams

Daily topical application to shoulders, upper arms, or inner thighs. Gels provide steady daily absorption and avoid the peaks and troughs of weekly injections. Key considerations: daily compliance required, transfer risk to partners and children (avoid skin contact until dry), and absorption can vary. Compounded testosterone creams from 503A pharmacies are available at significantly lower cost than branded options.

Subcutaneous pellets

Small pellets implanted subdermally every 3–6 months, providing sustained release without daily or weekly administration. No needles at home and highly consistent levels are the primary advantages. Requires an in-person minor procedure and is not available through telehealth platforms.

Transdermal patches

Daily patches (Androderm) provide a steady release profile but have higher rates of skin irritation compared to other delivery methods. Less commonly prescribed as a first-line option today given the alternatives available.

Oral testosterone (testosterone undecanoate)

Jatenzo is an FDA-approved oral testosterone undecanoate that avoids first-pass metabolism by absorbing via the lymphatic system. It requires twice-daily dosing with a meal and carries a specific prescribing consideration around blood pressure monitoring. Less commonly prescribed than injectables or topicals.

What does TRT monitoring look like?

Responsible TRT is not a set-and-forget prescription. Evidence-based monitoring includes:

• Testosterone levels: Checked 3–6 weeks after starting or after dose adjustments to confirm target range. Goal is typically mid-normal range (400–700 ng/dL total T in most protocols, though clinicians individualize based on symptoms and tolerability).
• Hematocrit: TRT can stimulate red blood cell production. Hematocrit above 54% (polycythemia) requires dose reduction or temporary hold. Checked every 3–6 months.
• PSA (men over 40–45): TRT can stimulate prostate tissue. A significant PSA increase prompts urological evaluation. This does not mean TRT causes prostate cancer — the evidence on this has evolved significantly — but PSA monitoring is standard practice.
• Estradiol: Testosterone aromatizes to estradiol. Some men convert at higher rates and may develop symptoms of estrogen excess (water retention, breast tissue sensitivity). Estradiol monitoring guides decisions about aromatase inhibitor use.
• Comprehensive metabolic panel: Standard safety monitoring.

A TRT program that does not include lab monitoring is not evidence-based care. It is a meaningful differentiator to ask prospective providers how frequently they check labs and what their protocols are for dose adjustments.

How does TRT affect fertility?

Exogenous testosterone suppresses LH and FSH — the pituitary hormones that signal the testes to produce testosterone and sperm. For men who may want to father children, this requires an explicit plan before starting TRT.

The most common approach is concurrent HCG (human chorionic gonadotropin), which mimics LH and maintains testicular function including sperm production. Some clinicians also add FSH supplementation in certain cases. Men who are actively trying to conceive may be better served by fertility-preserving protocols (clomiphene citrate, HCG monotherapy) rather than exogenous testosterone, which directly suppresses spermatogenesis.

This is not a minor consideration — have this conversation explicitly with your clinician before starting TRT if fertility is relevant to you now or in the future.

Frequently asked questions